Developer docs
API playgroundTry for free, no card

Search company profiles

Enlivex Therapeutics

Full company profile

uuid0003ohl

Namestring
Enlivex Therapeutics
Legal namestring
Enlivex Therapeutics Ltd.
Websiteurl
enlivex.com
Company typeenum
Public
Founded yearint
2005
Descriptiontext

Enlivex Therapeutics Ltd. (Nasdaq: ENLV) is an Israel-domiciled, clinical-stage biopharmaceutical company developing Allocetra, an off-the-shelf allogeneic cell therapy composed of mononuclear cells from non-HLA-matched healthy donors induced to an apoptotic state. Allocetra is designed to restore macrophage homeostasis by expressing phosphatidylserine as a primary "eat me" signal, and is currently in a global Phase IIb trial for moderate-to-severe age-related knee osteoarthritis under FDA IND clearance and Danish Medicines Agency approval, with trial sites in the United States, Denmark, and Poland. The therapeutic platform has been administered to over 250 patients across prior studies with a favorable safety profile, and Phase II data showed a 72% reduction in pain and a 109% improvement in function in knee osteoarthritis patients aged 60 and older; IP protection includes Australian Patent 2020340629 covering Allocetra in osteoarthritis through at least 2040.

Since November 2025, Enlivex has executed a strategic pivot to a dual-strategy model that overlays a digital asset treasury on its clinical operations. The company raised $212 million in a private placement and an additional $21 million in debt financing from The Lind Partners to acquire RAIN tokens — the governance and utility token of the Rain decentralized prediction-markets protocol on Arbitrum — at a roughly 55% discount to market via an option from the Rain Foundation exercisable through December 31, 2027. As of June 2026, the company held approximately 79.57 billion RAIN tokens valued at ~$1.14 billion, with Treasury NAV per Share of $4.67 against an equity market capitalization of roughly $188.5 million. RAIN has been listed on Gate, HTX, Kraken, and KuCoin, and ENLV ordinary shares have been tokenized on Ondo Global Markets to provide non-US investor access. The reported FY2025 net income of $1.23 billion is attributable entirely to unrealized appreciation of these treasury and treasury-related derivative assets (totaling $2.31 billion), not to operating revenue, and the company remains pre-revenue on its therapeutic program.

The company is led by CEO Dr. Oren Hershkovitz, CFO Shachar Shlosberger, CMO Dr. Einat Galamidi, and Executive Chairman Shai Novik; former Italian Prime Minister Matteo Renzi joined the Board in November 2025 to advise on treasury and policy strategy. Enlivex received a Nasdaq minimum bid price notice in May 2026 with a compliance period ending November 2026, signaling a near-term equity-listing risk that is material to investors given the divergence between the equity market cap and the underlying treasury NAV.

Short descriptiontext

Enlivex Therapeutics is a clinical-stage Israeli biotech developing Allocetra, an off-the-shelf macrophage-reprogramming cell therapy in Phase IIb for age-related knee osteoarthritis, which since late 2025 has overlaid a RAIN-token digital asset treasury strategy funded by a $212M private placement to anchor the company as a Nasdaq-listed vehicle for prediction-markets exposure.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNess Ziona, Israel
HQ citystring
Ness Ziona
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cell therapy immunotherapy, macrophage reprogramming, osteoarthritis treatment, digital asset treasury, prediction markets protocol
Industry1 code
PRIMARYFSADABAM
Prediction Markets & Event-Based On-Chain Trading
Financial & Insurance/Crypto & Digital Assets/Decentralized Exchanges (DEX) & On-Chain Trading
NAICS code3 codes
  • Securities and Commodity Exchanges52321
  • Investment Banking and Securities Intermediation523150
  • Miscellaneous Intermediation523910
SIC code1 code
  • Security & Commodity Brokers, Dealers, Exchanges & Services6200
Product category
Clinical-Stage Cell Therapy Immunotherapy
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Digital Asset Treasury Appreciation
TypeData Monetisation
Description

The company generates gains through appreciation of its RAIN token holdings. Treasury and treasury-related derivative assets reached $2.31 billion. Net income of $1.23 billion and diluted EPS of $25.48 reported for FY 2025, driven by unrealized appreciation in treasury assets.

globenewswire.com
2Clinical Development Pipeline
TypeLicensing Royalties
Description

Pre-commercial stage. Allocetra is in Phase IIb clinical trials for knee osteoarthritis. No therapeutic revenue yet. The company continues advancing clinical development of its immunotherapy programs targeting inflammatory conditions associated with aging.

investors.enlivex.com
3Token Listing and Exchange Services
TypeTransaction Fee
Description

The company benefits from RAIN token listings on cryptocurrency exchanges (Gate, HTX, Kraken, KuCoin), which expand market access and secondary liquidity for its treasury assets.

theblock.co
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Enlivex is a clinical-stage biopharmaceutical company developing Allocetra™, an off-the-shelf, allogeneic cell therapy composed of apoptotic mononuclear cells designed to reprogram macrophages and restore immune homeostasis, with Phase IIb trials underway for moderate-to-severe age-related knee osteoarthritis. In parallel, the company operates a digital asset treasury strategy anchored in RAIN tokens—the governance and utility token of the Rain decentralized prediction markets protocol built on Arbitrum—providing institutional investors with public-market exposure to prediction markets infrastructure through Nasdaq-listed ENLV shares.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 72% reduction in pain and 109% improvement in function in Phase IIa knee osteoarthritis trial
+2 more records
Product overview1 text field

Enlivex Therapeutics operates as a quality longevity company with a dual-strategy model combining clinical development with a digital asset treasury. The company's core clinical product is Allocetra™, an off-the-shelf allogeneic cell therapy targeting macrophage homeostasis for treatment of age-related osteoarthritis. Alongside its clinical programs, Enlivex operates a prediction markets treasury strategy built around the Rain (RAIN) protocol on Arbitrum, holding significant RAIN token reserves as digital capital assets. The company positions itself as the first publicly traded company providing investors exposure to decentralized prediction markets infrastructure.

Product and service2 records
1Allocetra™
CategoryCell therapy immunotherapy
Description

Off-the-shelf, allogeneic cell therapy composed of mononuclear cells derived from non-HLA matched healthy donors and induced to an apoptotic state. The therapy expresses phosphatidylserine (PtdSer), a primary 'eat me' signal that triggers macrophage modulation and restores homeostatic state. Designed for intravenous infusion or intra-articular injection to treat inflammatory conditions including moderate-to-severe age-related knee osteoarthritis and sepsis. Currently in Phase IIb clinical trials across the U.S., Denmark, and Poland.

2RAIN Token Digital Asset Treasury
CategoryDigital asset treasury
Description

Corporate digital asset treasury strategy anchoring Enlivex's reserves in RAIN, the governance and utility token of the Rain decentralized prediction markets protocol on the Arbitrum network. The treasury held approximately 79.57 billion RAIN tokens valued at roughly $1.14 billion as of June 20, 2026, with a Treasury NAV per Share of $4.67. Provides investors with public-market access to prediction markets infrastructure via Nasdaq-listed ENLV shares.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-04-29
Description

RAIN token listed on HTX, one of the world's largest digital asset platforms serving over 160 countries with approximately $3.3 trillion in annual trading volume and 59 million users.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-04-08
Description

Enlivex's ordinary shares tokenized and launched on Ondo Global Markets' platform, allowing non-US investors to gain exposure to the company's shares through digital infrastructure.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-02-09
Description

RAIN token listed on Kraken, the second-largest US-based cryptocurrency exchange, increasing token access and expanding secondary market liquidity.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-01-01
Description

RAIN token listed on KuCoin cryptocurrency exchange, expanding global market access and secondary liquidity for Enlivex's digital asset treasury holding.

Strategic tierSupportingTypeImplementation/ SI/ Consulting PartnerAnnounced on2025-11-24
Description

Legal counsel advising Enlivex on $212 million private placement to fund adoption of RAIN prediction markets token treasury strategy.

6Matteo Renzi (Former Italian Prime Minister)
Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2025-11-24
Description

Appointed to Board of Directors effective November 24, 2025, to assist with treasury and policy strategy as the company implements its prediction markets digital asset treasury strategy.

enlivex.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic partnership providing option to acquire up to 272 billion RAIN tokens at discounted prices. Tokens purchased at $0.0033 per RAIN, representing approximately 55% discount to market price. Option exercisable through December 31, 2027.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

RAIN token listed on Gate exchange, ranked second globally in 24-hour spot trading volume with over 54 million users. Listing expands market access and secondary liquidity for Enlivex's primary treasury asset.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

The pioneer and most prominent public company using its balance sheet to accumulate a single crypto asset (Bitcoin) as a treasury reserve. Enlivex mirrors this model with RAIN, including the use of capital raises and convertible debt to acquire discounted tokens, and equity trading at a discount to underlying asset value.

TypeDirect peer
Description

Public digital asset company with a treasury anchored in Bitcoin. Enlivex shares the playbook of raising capital to accumulate a single on-chain asset and trading at NAV-discounted valuations, though Marathon's asset is BTC versus Enlivex's RAIN.

TypeDirect peer
Description

The largest decentralized prediction markets protocol. Enlivex's entire treasury thesis rests on Rain's ability to compete against Polymarket; the two are direct rivals in the on-chain event-contract category.

TypeDirect peer
Description

CFTC-regulated U.S. prediction market exchange. Kalshi is the regulated, fiat-native counterpart to Rain, and a key competitor for institutional flow that Enlivex is positioning to capture via public equity exposure.

TypeBroad incumbent
Description

Largest U.S.-listed crypto exchange, including listings of RAIN tokens that support Enlivex's secondary liquidity. Operates in the broader digital-asset infrastructure stack that Enlivex's treasury strategy depends on.

TypeEmerging player
Description

Earlier-generation decentralized prediction market protocol. Competes with Rain for on-chain prediction market share and represents the technical lineage Enlivex is indirectly exposed to through its RAIN holdings.

TypeDirect peer
Description

Public digital asset company holding significant Bitcoin reserves on its balance sheet. Enlivex follows the same public-company-as-crypto-treasury template, with a different underlying token.

8Pluristem Therapeutics
TypeRegional player
Description

Israel-based clinical-stage cell therapy company. Directly comparable to Enlivex's legacy biopharmaceutical identity (allogeneic cell therapy targeting inflammatory conditions) prior to the crypto treasury pivot, and a useful benchmark for the pre-pivot Enlivex equity story.

TypeDirect peer
Description

Clinical-stage allogeneic cell therapy company with late-stage trials in inflammatory conditions. Comparable to the Allocetra platform in modality (off-the-shelf cell therapy) and regulatory stage (Phase IIb/III).

TypeBroad incumbent
Description

Public crypto-focused financial services and asset management firm. Enlivex's hybrid model (capital markets access + digital asset treasury + institutional investor focus) most closely mirrors Galaxy's broader market profile, though at a much earlier stage.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds12 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Enlivex Therapeutics

Clinical-Stage Cell Therapy Immunotherapyenlivex.com

Enlivex Therapeutics is a clinical-stage Israeli biotech developing Allocetra, an off-the-shelf macrophage-reprogramming cell therapy in Phase IIb for age-related knee osteoarthritis, which since late 2025 has overlaid a RAIN-token digital asset treasury strategy funded by a $212M private placement to anchor the company as a Nasdaq-listed vehicle for prediction-markets exposure.

What Enlivex Therapeutics does

Enlivex Therapeutics Ltd. (Nasdaq: ENLV) is an Israel-domiciled, clinical-stage biopharmaceutical company developing Allocetra, an off-the-shelf allogeneic cell therapy composed of mononuclear cells from non-HLA-matched healthy donors induced to an apoptotic state. Allocetra is designed to restore macrophage homeostasis by expressing phosphatidylserine as a primary "eat me" signal, and is currently in a global Phase IIb trial for moderate-to-severe age-related knee osteoarthritis under FDA IND clearance and Danish Medicines Agency approval, with trial sites in the United States, Denmark, and Poland. The therapeutic platform has been administered to over 250 patients across prior studies with a favorable safety profile, and Phase II data showed a 72% reduction in pain and a 109% improvement in function in knee osteoarthritis patients aged 60 and older; IP protection includes Australian Patent 2020340629 covering Allocetra in osteoarthritis through at least 2040.

Since November 2025, Enlivex has executed a strategic pivot to a dual-strategy model that overlays a digital asset treasury on its clinical operations. The company raised $212 million in a private placement and an additional $21 million in debt financing from The Lind Partners to acquire RAIN tokens — the governance and utility token of the Rain decentralized prediction-markets protocol on Arbitrum — at a roughly 55% discount to market via an option from the Rain Foundation exercisable through December 31, 2027. As of June 2026, the company held approximately 79.57 billion RAIN tokens valued at ~$1.14 billion, with Treasury NAV per Share of $4.67 against an equity market capitalization of roughly $188.5 million. RAIN has been listed on Gate, HTX, Kraken, and KuCoin, and ENLV ordinary shares have been tokenized on Ondo Global Markets to provide non-US investor access. The reported FY2025 net income of $1.23 billion is attributable entirely to unrealized appreciation of these treasury and treasury-related derivative assets (totaling $2.31 billion), not to operating revenue, and the company remains pre-revenue on its therapeutic program.

The company is led by CEO Dr. Oren Hershkovitz, CFO Shachar Shlosberger, CMO Dr. Einat Galamidi, and Executive Chairman Shai Novik; former Italian Prime Minister Matteo Renzi joined the Board in November 2025 to advise on treasury and policy strategy. Enlivex received a Nasdaq minimum bid price notice in May 2026 with a compliance period ending November 2026, signaling a near-term equity-listing risk that is material to investors given the divergence between the equity market cap and the underlying treasury NAV.

Enlivex Therapeutics firmographics

Firmographics
Name
Enlivex Therapeutics
Legal name
Enlivex Therapeutics Ltd.
Website
https://enlivex.com
Company type
Public
Founded year
2005
Operating status
Operating
Headcount range
11–50 employees
Short description
Enlivex Therapeutics is a clinical-stage Israeli biotech developing Allocetra, an off-the-shelf macrophage-reprogramming cell therapy in Phase IIb for age-related knee osteoarthritis, which since late 2025 has overlaid a RAIN-token digital asset treasury strategy funded by a $212M private placement to anchor the company as a Nasdaq-listed vehicle for prediction-markets exposure.
Ownership category
akta.pro rank

Enlivex Therapeutics industry classification

Industry
Product category
Clinical-Stage Cell Therapy Immunotherapy
NAICS
Securities and Commodity Exchanges (52321), Investment Banking and Securities Intermediation (523150), Miscellaneous Intermediation (523910)
SIC
Security & Commodity Brokers, Dealers, Exchanges & Services (6200)
akta.pro industry
PRIMARYFSADABAM
Prediction Markets & Event-Based On-Chain Trading
Financial & Insurance/Crypto & Digital Assets/Decentralized Exchanges (DEX) & On-Chain Trading

Keywords

  • Cell therapy immunotherapy
  • Macrophage reprogramming
  • Osteoarthritis treatment
  • Digital asset treasury
  • Prediction markets protocol

Where Enlivex Therapeutics is headquartered

Location

Headquarters

HQ city
Ness Ziona
HQ country
Israel
HQ region
Middle East

Offices1 record

Markets served

Enlivex Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Digital Asset Treasury Appreciation: The company generates gains through appreciation of its RAIN token holdings. Treasury and treasury-related derivative assets reached $2.31 billion. Net income of $1.23 billion and diluted EPS of $25.48 reported for FY 2025, driven by unrealized appreciation in treasury assets.
  2. Clinical Development Pipeline: Pre-commercial stage. Allocetra is in Phase IIb clinical trials for knee osteoarthritis. No therapeutic revenue yet. The company continues advancing clinical development of its immunotherapy programs targeting inflammatory conditions associated with aging.
  3. Token Listing and Exchange Services: The company benefits from RAIN token listings on cryptocurrency exchanges (Gate, HTX, Kraken, KuCoin), which expand market access and secondary liquidity for its treasury assets.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Enlivex Therapeutics product offering

Product offering

Core offering

Enlivex is a clinical-stage biopharmaceutical company developing Allocetra™, an off-the-shelf, allogeneic cell therapy composed of apoptotic mononuclear cells designed to reprogram macrophages and restore immune homeostasis, with Phase IIb trials underway for moderate-to-severe age-related knee osteoarthritis. In parallel, the company operates a digital asset treasury strategy anchored in RAIN tokens—the governance and utility token of the Rain decentralized prediction markets protocol built on Arbitrum—providing institutional investors with public-market exposure to prediction markets infrastructure through Nasdaq-listed ENLV shares.

Product overview

Enlivex Therapeutics operates as a quality longevity company with a dual-strategy model combining clinical development with a digital asset treasury. The company's core clinical product is Allocetra™, an off-the-shelf allogeneic cell therapy targeting macrophage homeostasis for treatment of age-related osteoarthritis. Alongside its clinical programs, Enlivex operates a prediction markets treasury strategy built around the Rain (RAIN) protocol on Arbitrum, holding significant RAIN token reserves as digital capital assets. The company positions itself as the first publicly traded company providing investors exposure to decentralized prediction markets infrastructure.

Differentiator

Problem solved

Functional benefit

Products and services

  • Allocetra™ Off-the-shelf, allogeneic cell therapy composed of mononuclear cells derived from non-HLA matched healthy donors and induced to an apoptotic state. The therapy expresses phosphatidylserine (PtdSer), a primary 'eat me' signal that triggers macrophage modulation and restores homeostatic state. Designed for intravenous infusion or intra-articular injection to treat inflammatory conditions including moderate-to-severe age-related knee osteoarthritis and sepsis. Currently in Phase IIb clinical trials across the U.S., Denmark, and Poland.
  • RAIN Token Digital Asset Treasury Corporate digital asset treasury strategy anchoring Enlivex's reserves in RAIN, the governance and utility token of the Rain decentralized prediction markets protocol on the Arbitrum network. The treasury held approximately 79.57 billion RAIN tokens valued at roughly $1.14 billion as of June 20, 2026, with a Treasury NAV per Share of $4.67. Provides investors with public-market access to prediction markets infrastructure via Nasdaq-listed ENLV shares.

Quantifiable outcome

  • 72% reduction in pain and 109% improvement in function in Phase IIa knee osteoarthritis trial
  • +2 more outcomes

Companies that use Enlivex Therapeutics

Customer profile

Segments2 records

Ideal customer profiles2 records

Enlivex Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Enlivex Therapeutics partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and supporting.

  • HTX Cryptocurrency ExchangecoreChannel Partner/ Reseller/ Distributor · 29 April 2026RAIN token listed on HTX, one of the world's largest digital asset platforms serving over 160 countries with approximately $3.3 trillion in annual trading volume and 59 million users.
  • Ondo Global MarketscoreTechnology or Integration · 8 April 2026Enlivex's ordinary shares tokenized and launched on Ondo Global Markets' platform, allowing non-US investors to gain exposure to the company's shares through digital infrastructure.
  • Kraken Cryptocurrency ExchangecoreChannel Partner/ Reseller/ Distributor · 9 February 2026RAIN token listed on Kraken, the second-largest US-based cryptocurrency exchange, increasing token access and expanding secondary market liquidity.
  • KuCoin Cryptocurrency ExchangecoreChannel Partner/ Reseller/ Distributor · 1 January 2026RAIN token listed on KuCoin cryptocurrency exchange, expanding global market access and secondary liquidity for Enlivex's digital asset treasury holding.
  • Greenberg TraurigsupportingImplementation/ SI/ Consulting Partner · 24 November 2025Legal counsel advising Enlivex on $212 million private placement to fund adoption of RAIN prediction markets token treasury strategy.
  • Matteo Renzi (Former Italian Prime Minister)supportingStrategic or Co-development Partner · 24 November 2025Appointed to Board of Directors effective November 24, 2025, to assist with treasury and policy strategy as the company implements its prediction markets digital asset treasury strategy.
  • Rain FoundationcoreStrategic or Co-development PartnerStrategic partnership providing option to acquire up to 272 billion RAIN tokens at discounted prices. Tokens purchased at $0.0033 per RAIN, representing approximately 55% discount to market price. Option exercisable through December 31, 2027.
  • Gate Cryptocurrency ExchangecoreChannel Partner/ Reseller/ DistributorRAIN token listed on Gate exchange, ranked second globally in 24-hour spot trading volume with over 54 million users. Listing expands market access and secondary liquidity for Enlivex's primary treasury asset.

Scale indicators10 records

Recent moves6 records

Expansion highlights5 records

Enlivex Therapeutics competitors and assessment

Company assessment

Direct peers

  • MicroStrategy: The pioneer and most prominent public company using its balance sheet to accumulate a single crypto asset (Bitcoin) as a treasury reserve. Enlivex mirrors this model with RAIN, including the use of capital raises and convertible debt to acquire discounted tokens, and equity trading at a discount to underlying asset value.
  • Marathon Digital Holdings: Public digital asset company with a treasury anchored in Bitcoin. Enlivex shares the playbook of raising capital to accumulate a single on-chain asset and trading at NAV-discounted valuations, though Marathon's asset is BTC versus Enlivex's RAIN.
  • Polymarket: The largest decentralized prediction markets protocol. Enlivex's entire treasury thesis rests on Rain's ability to compete against Polymarket; the two are direct rivals in the on-chain event-contract category.
  • Kalshi: CFTC-regulated U.S. prediction market exchange. Kalshi is the regulated, fiat-native counterpart to Rain, and a key competitor for institutional flow that Enlivex is positioning to capture via public equity exposure.
  • Riot Platforms: Public digital asset company holding significant Bitcoin reserves on its balance sheet. Enlivex follows the same public-company-as-crypto-treasury template, with a different underlying token.
  • Mesoblast: Clinical-stage allogeneic cell therapy company with late-stage trials in inflammatory conditions. Comparable to the Allocetra platform in modality (off-the-shelf cell therapy) and regulatory stage (Phase IIb/III).

Broad incumbents

  • Coinbase Global: Largest U.S.-listed crypto exchange, including listings of RAIN tokens that support Enlivex's secondary liquidity. Operates in the broader digital-asset infrastructure stack that Enlivex's treasury strategy depends on.
  • Galaxy Digital: Public crypto-focused financial services and asset management firm. Enlivex's hybrid model (capital markets access + digital asset treasury + institutional investor focus) most closely mirrors Galaxy's broader market profile, though at a much earlier stage.

Emerging players

  • Augur / Threshold Network: Earlier-generation decentralized prediction market protocol. Competes with Rain for on-chain prediction market share and represents the technical lineage Enlivex is indirectly exposed to through its RAIN holdings.

Regional players

  • Pluristem Therapeutics: Israel-based clinical-stage cell therapy company. Directly comparable to Enlivex's legacy biopharmaceutical identity (allogeneic cell therapy targeting inflammatory conditions) prior to the crypto treasury pivot, and a useful benchmark for the pre-pivot Enlivex equity story.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Enlivex Therapeutics social profiles

Digital presence

Enlivex Therapeutics compliance and trust

Trust signal

Compliance1 record

Enlivex Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Enlivex Therapeutics leadership team

Management profile

Number of profiles

Profiles7 records

Enlivex Therapeutics funding detail

Funding detail

Funding overview

Funding rounds12 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Enlivex Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Enlivex Therapeutics

What does Enlivex Therapeutics do?

Enlivex is a clinical-stage biopharmaceutical company developing Allocetra™, an off-the-shelf, allogeneic cell therapy composed of apoptotic mononuclear cells designed to reprogram macrophages and restore immune homeostasis, with Phase IIb trials underway for moderate-to-severe age-related knee osteoarthritis. In parallel, the company operates a digital asset treasury strategy anchored in RAIN tokens—the governance and utility token of the Rain decentralized prediction markets protocol built on Arbitrum—providing institutional investors with public-market exposure to prediction markets infrastructure through Nasdaq-listed ENLV shares.

Is Enlivex Therapeutics a public or private company?

Enlivex Therapeutics is a public company. It is classified as public and is currently operating.

When was Enlivex Therapeutics founded?

Enlivex Therapeutics was founded in 2005. It employs 11 to 50 people.

Where is Enlivex Therapeutics based?

Enlivex Therapeutics is headquartered in Ness Ziona, Israel, in the Middle East region.

How does Enlivex Therapeutics make money?

Three revenue lines are on record. Digital Asset Treasury Appreciation is the primary driver. The others are clinical Development Pipeline and token Listing and Exchange Services.

Who are Enlivex Therapeutics's main competitors?

Direct peers on record are MicroStrategy, Marathon Digital Holdings, Polymarket, Kalshi, Riot Platforms and Mesoblast. Broad incumbents are Coinbase Global and Galaxy Digital. Augur / Threshold Network is listed as an emerging player. Pluristem Therapeutics is listed as a regional player.

Does Enlivex Therapeutics have an API?

No public API is recorded for Enlivex Therapeutics.

What industry is Enlivex Therapeutics in?

Enlivex Therapeutics's product category is Clinical-Stage Cell Therapy Immunotherapy. Its primary akta.pro industry code is FSADABAM, Prediction Markets & Event-Based On-Chain Trading. Its NAICS code is 52321 and its SIC code is 6200.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MarketScreenerEnlivex Ltd. Announces Positive Interim DSMB Safety Review Supporting Continued Enrollment In Phase IIb Knee Osteoarthritis TrialEnlivex Ltd. announced that its DSMB completed an interim safety review of 85 patients in the Phase IIb trial of Allocetra for knee osteoarthritis. The review confirmed the safety profile allows continued enrollment as planned. The trial plans to enroll about 182 patients from the US, Denmark, and Poland.TradingViewEnlivex prices $7.5M registered direct offeringEnlivex agreed to raise $7.5M via a registered direct offering of ordinary shares and pre-funded warrants, priced at a 10.5% premium to the Nov. 13 closing price. The offering spans 11 closings, starting with a $500K initial closing on Nov. 17 and monthly $700K investments through September 2027. Proceeds will fund clinical, regulatory, manufacturing, and R&D activities.Dealroom.coEnlivex raises $7.5M in staggered share offering priced above market | Dealroom NewsEnlivex Therapeutics agreed to sell $7.5 million of ordinary shares and warrants in a staggered offering priced at $1.315 per share, a 10.5% premium to its November 13 Nasdaq closing price. The company will receive $500,000 initially and $700,000 monthly from December 2026 through September 2027, with proceeds for clinical, regulatory, and research activities.Seeking AlphaEnlivex faces Nasdaq delisting risk, plans appeal (ENLV:NASDAQ)Enlivex received a Nasdaq delisting notice for failing to meet the $1 minimum bid price for 30 consecutive days. The company plans to appeal by requesting an oral hearing, which will stay suspension or delisting. It implemented a 1-for-16 reverse share split to support compliance.Business & FinancialEnlivex Announces Receipt Of Delisting Notice From Nasdaq Intends To AppealEnlivex announced it will appeal Nasdaq's delisting determination by requesting an oral hearing, which will stay any suspension pending the hearing. The company also effected a 1-for-16 reverse split of its ordinary shares, effective today. It cannot assure the appeal will succeed or that shares will remain listed.The future of tradingEnlivex Implements 1-for-16 Reverse Stock SplitEnlivex will implement a 1-for-16 reverse stock split effective Oct. 27, 2026, to regain Nasdaq listing compliance. Nasdaq issued a delisting notice over failure to meet the $1 minimum bid price, and a planned appeal would stay suspension pending a hearing.Seeking AlphaEnlivex announces 1-for-16 reverse stock split (ENLV:NASDAQ)Enlivex will implement a 1-for-16 reverse stock split effective October 27, 2026, with shares trading on a split-adjusted basis on Nasdaq. The company's issued and outstanding shares will decrease from approximately 24.51 million to 1.53 million, and authorized shares will be reduced proportionately.TradingViewEnlivex announces 1-for-16 reverse stock splitEnlivex will implement a 1-for-16 reverse stock split effective October 27, 2026, with shares trading on a split-adjusted basis on Nasdaq. The company's issued and outstanding shares will decrease from approximately 24.51 million to 1.53 million, and authorized shares from 158.33 million to about 9.90 million. The par value per ordinary share will increase from NIS 6.00 to NIS 96.00.Quiver QuantitativeEnlivex Ltd. Announces 1-for-16 Reverse Stock Split Effective October 27, 2026 | ENLV Stock NewsEnlivex Ltd. announced a 1-for-16 reverse stock split effective October 27, 2026, on Nasdaq. The split reduces issued shares from about 24.5 million to 1.5 million and cuts authorized shares from 158.3 million to 9.9 million, while raising par value to NIS 96.00. The company continues advancing its Allocetra™ immunotherapy program.Business & FinancialEnlivex Announces 1-For-16 Reverse Share Split To Be Effective October 27, 2026Enlivex announced a 1-for-16 reverse share split effective October 27, 2026, combining 16 shares into one. The split reduces authorized shares from 158,333,333 to 9,895,833 and increases par value from NIS 6.00 to NIS 96.00, while issued shares fall from 24,511,905 to about 1,531,995. No fractional shares will be issued; fractional shares are rounded up.